The Spartanburg Community Clinical Oncology Program (SCCOP) has been an enthusiastic participant in the CCOP program since its inception. Since 1983 SCCOP has accrued greater than 10% of all newly diagnosed cancer patients in our regional tumor registry to cancer treatment protocols with data of high quality and low cost per accrual in this rural CCOP. The average accrual per year of 102 compares favorably with the average yearly treatment accrual CCOP wide of 86 as stated in the RFA. The SCCOP accrued 100 subjects to cancer control protocols in FY-06, equivalent to the average accrual CCOP wide of 109.6 subjects per year as stated in the RFA. SCCOP believes that participation in NCI approved cancer treatment and cancer control protocol activities is an ideal way to bring state-of-the- art cancer treatment and cancer control research to members of our community and involve a wider segment of our community in such activities. This participation will transfer newly developed technology in cancer prevention, early detection, treatment, patient management, rehabilitation and continuing care to our community in an accelerated fashion and correspondingly reduce cancer incidence, morbidity and mortality. The goals of the SCCOP for this grant period are to maintain and expand our cancer treatment accruals and to develop a comprehensive cancer control trials program. This will be accomplished by enlisting a larger number of subspecialty investigators (ENT, urology, surgical oncology, gynecology) in cancer treatment and cancer control activities, and encompassing both the family practice residency program at Spartanburg Regional Medical Center and private practice primary care physicians in cancer control activities. The SCCOP will continue to affiliate with SWOG, CCWFU, NSABP, and MDACC as research bases. The grant will support three full-time equivalents for data management. The consortium hospitals, as a measure of their commitment to the CCOP program, are providing significant funding for one FTE (secretary/data manager) and additional funds for travel and cancer control data management activities. The SCCOP enthusiastically recompetes at this time for continued funding for an activity which has proven extremely rewarding for this community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035119-10
Application #
3557530
Study Section
Special Emphasis Panel (SRC (48))
Project Start
1983-09-01
Project End
1996-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 202 publications